Xponance Inc. Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Xponance Inc. increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% in the 4th quarter, HoldingsChannel reports. The fund owned 83,510 shares of the medical equipment provider’s stock after purchasing an additional 165 shares during the quarter. Xponance Inc.’s holdings in Intuitive Surgical were worth $28,173,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Liberty Capital Management Inc. lifted its position in shares of Intuitive Surgical by 3.8% during the 4th quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 30 shares during the period. Miracle Mile Advisors LLC lifted its position in shares of Intuitive Surgical by 2.3% during the 4th quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock valued at $485,000 after acquiring an additional 32 shares during the period. Ausdal Financial Partners Inc. lifted its position in shares of Intuitive Surgical by 1.5% during the 4th quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock valued at $739,000 after acquiring an additional 33 shares during the period. Venturi Wealth Management LLC lifted its position in shares of Intuitive Surgical by 10.7% during the 4th quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 33 shares during the period. Finally, Modera Wealth Management LLC raised its position in shares of Intuitive Surgical by 2.0% during the 3rd quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock worth $501,000 after purchasing an additional 34 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In related news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. Insiders sold a total of 248,418 shares of company stock valued at $95,927,097 in the last quarter. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded down $1.54 during trading on Thursday, reaching $372.63. The company had a trading volume of 2,264,805 shares, compared to its average volume of 1,639,282. The company has a market cap of $132.08 billion, a price-to-earnings ratio of 74.39, a price-to-earnings-growth ratio of 5.88 and a beta of 1.36. The firm’s fifty day moving average is $387.56 and its 200-day moving average is $342.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.89 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.91 EPS. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several research reports. Royal Bank of Canada lifted their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Mizuho lifted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Citigroup lifted their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus lifted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Truist Financial lifted their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $375.70.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.